# A Study To Access The Safety And Tolerability Of RN316 (PF-04950615) When Administered To Healthy Adult Subjects

> **NCT00991159** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 48 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** RN316

## Key facts

- **NCT ID:** NCT00991159
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2012-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00991159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00991159, "A Study To Access The Safety And Tolerability Of RN316 (PF-04950615) When Administered To Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00991159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*